Stem Cell Clinic

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer – PRNewswire

CAMBRIDGE, Mass., Jan. 29, 2021 /PRNewswire/ --Exacis Biotherapeutics, Inc., a development-stageimmuno-oncology company working to harness the immune system to cure cancer,today announcedthe addition of Dirk Huebner,MD,as its Chief Medical Officer. Exacis launched in 2020 to develop next generation mRNA-based cellular therapeutics to treat liquid and solid tumors.

Exacis CEO Gregory Fiore MD said, "Dirk is a wonderful addition and a great fit for our management team. His extensive experience in oncology drug development, including antibody related therapies will be instrumental as we build our pipeline to include high performance stealth edited NK and T cells, with and without CARs (ExaNK, ExaCAR-NK and ExaCAR-T). We look forward to Dirk's insights and medical leadership as we build the company and advance our portfolio."

Dr. Huebner joins Exacis from Mersana Therapeutics where he wasthe Chief Medical Officer,oversaw their clinical developmentand helped build thecompany'sclinical infrastructure. Dr Huebnerhas worked in oncology and immuno-oncology drug development and academiafor more than 25 yearsand brings a deep understanding of the needs in the oncology space as well as the ability to successfully deliverproducts to meet those needs.

Commenting on the new role, Dr. Huebner said, "I am thrilled to join the Exacis team and work with best-in-class technology to create innovative, next-generation engineered NK and T cell therapies that have the potential to improve outcomes and treatment experiences for patients with challenging hematologic and solid tumor malignancies."

About Exacis Biotherapeutics

Exacis is a development stageimmuno-oncologycompany focused on harnessing the human immune system to cure cancer. Exacis uses its proprietary mRNA-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors.Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use ofmRNA-based cell reprogramming and gene editing technologiesfor oncology.

ExaNK, ExaCAR-NK and ExaCAR-T utilize mRNA cell reprogramming and mRNA gene editing technologies developed and owned by Factor Bioscience. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all global development and commercial rights for these investigational candidates.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

SOURCE Exacis Biotherapeutics, Inc.

See the original post:
Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - PRNewswire

Induced Pluripotent Stem Cells Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast…

To survive in a challenging and continuously transforming environment collecting, analyzing, and evaluating data becomes a key task to overcome obstacles and support the decision-making aspects of a business. Research documents or reports are a convenient medium to understand and analyze how a specific market is projected to perform in the coming years.

Why Choose DataIntelo?

DataIntelo, one of the worlds prominent market research firms has rolled out a new report on the Induced Pluripotent Stem Cells Market. The report is full of crucial insights on the market which will help the clients in making correct business decisions. This research will help both existing and new aspirants for Induced Pluripotent Stem Cells market to figure out and study market requirements, market size, and competition. The report includes the supply and demand scenario, the competitive market scene, and challenges for market growth, market opportunities, and the restraints faced by key players.

Request Free Exclusive Sample on Induced Pluripotent Stem Cells Market Report @ https://dataintelo.com/request-sample/?reportId=77310

The report is also integrated with the impact of the ongoing global crisis i.e. COVID-19 on the Induced Pluripotent Stem Cells market and how the pandemic is tweaking the market trends and situation. The published report is designed with the help of a vigorous and thorough research methodology. DataIntelo is also popular for its data accuracy and granular market reports. A complete picture of the competitive scenario of the Induced Pluripotent Stem Cells market is presented by this report. The report has a substantial amount of data about the recent product and technological developments in the markets. It has a wide spectrum of analysis regarding the impact of these advancements on the markets future growth, government policies, norms, and regulations that have and can affect the dynamics of the market.

The historical and forecast information provided in the report ranges between 2020 and 2027. It also includes data fluctuating according to region and country. The insights in the report are simple, easy to understand, include pictorial representations, and infographics. These insights are also suitable for real-time scenarios. Components such as market drivers, restraints, challenges, and opportunities for Induced Pluripotent Stem Cells are explained in detail. Since our research team is tracking the data for the market from 2017, therefore any additional data requirement can be easily fulfilled.

Purchase a copy of this report at: https://dataintelo.com/checkout/?reportId=77310

Some of the prominent companies that are covered in this report:

Fujifilm Holding Corporation Astellas Pharma Fate Therapeutics Bristol-Myers Squibb Company ViaCyte Celgene Corporation Aastrom Biosciences Acelity Holdings StemCells Japan Tissue Engineering Organogenesis

*Note: Additional companies can be included on request

The industry seems to be evenly competitive. To analyze any market with simplicity the market is divided into segments, such as its product type, application, technology, end-user, etc. Segmenting the market into smaller components makes it easier in understanding the dynamics of the market with more transparency. Data is depicted with the help of tables and figures that consist of a graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc. Another major component that is integrated with the report is the regional analysis to assess the global presence of the Induced Pluripotent Stem Cellsmarket.

Following is the gist of segmentation:

By Applications:

Academic Research Drug Development And Discovery Toxicity Screening Regenerative Medicine

By Types:

Hepatocytes Fibroblasts Keratinocytes Amniotic Cells Others

By Regions:

North America: U.S. and Canada

Asia Pacific: India, China, Japan, and Rest of Asia Pacific

Europe: Germany, France, Italy, the UK, and Rest of Europe

Latin America: Brazil, Cuba, Argentina, and Rest of Latin America

Middle East & Africa: South Africa, Saudi Arabia, and Rest of Middle East & Africa

You can also go for a yearly subscription to all the updates on the Induced Pluripotent Stem Cells market.

Reasons you should buy this report:

Below is the TOC of the Report:

If you have any questions on this report, please reach out to usFor any queries on this report: https://dataintelo.com/enquiry-before-buying/?reportId=77310

About DataIntelo:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email: [emailprotected]

Website: https://dataintelo.com

More here:
Induced Pluripotent Stem Cells Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast...

Money on the Move: January 27 February 2 – BioSpace

The groundhog saw his shadow, meaning six more weeks of winter. But there's no freezing of funds in the biopharma world. Here's a recap of where life sciencescash has been flowing the past week.

Sana Biotechnology

Initially filing for a$150 million IPO, Seattle-based Sanaamendedto amassivegoal of$323 million,offering 15 million shares at $20 to $23 per share.Although the company is still at a preclinical stage,this IPOwould value the company at a price of nearly $4.5 billion.Prime focuses of startup company Sana Biotechnology include the development ofin vivoandex vivocell engineering platformslicensedfrom Harvard University to discover novel treatments across several therapeutic areas that currently have unmet treatment needs. Therapeutic areas of particular interest to the company include oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases and genetic disorders. IND applications are anticipated in 2022 and 2023. Last summer Sana raised$700 million ininitial financing.

Design Therapeutics

Launched last Marchwith $45 million to create a new class of disease-modifying therapies,Design Therapeutics secured another$125 million this week in a Series B.In the short time since our launch, Design Therapeutics has made significant progress in the advancement of our novelGeneTACplatform focused on addressing the underlying causes of serious degenerative diseases, said Joo Siffert, M.D., president and chief executive officer of Design Therapeutics. This capital raise provides important resources to efficiently advance our pipeline, including our lead programs in Friedreich ataxia and myotonic dystrophy type-1. Proceeds will be used to advance theGeneTACplatform to develop a pipeline ofGeneTACmolecules with an initial focus on nucleotide repeat expansion disorders, including Friedreich ataxia. Design hopes to be in the clinic by the first half of 2022.

Nuvalent

Launching with a$50 million Series A,Nuvalentistackling the most common type of lung cancer NSCLC. The funds raised will fuelNuvalentsR&D efforts towardbuildinga portfolioof innovative small molecule kinase inhibitors for programs in NSCLC. Therapeuticagents include a potential best-in-class ROS1-selective inhibitor, NUV-520, and an ALK-selective inhibitor, NUV-655.The companys first lead program involving NUV-520 will examine the molecules efficacy in treating advanced NSCLC, particularly cases that have developed resistance to treatment, driven by a ROS1 fusion. The first Phase I/II trial investigating the potential therapy in NSCLC is expected for the second half of this year. Another program targeting NSCLC tumors driven by an ALK fusion is anticipated in 2022.

Ukko

On a mission to eliminate food allergies and sensitivities, a massive needs market, Ukko scooped up$40 million in a Series B round.Using an AI-driven protein engineering platform, the company isdevelopinga promising investigational therapy for peanut allergies.Ukko is also working on an improved gluten for people with Celiac disease and other gluten sensitivities to be able to enjoy.Data on both of these programs suggest these do not trigger allergic responses in the immune systems of patients. The new fundingwilltake Ukko to clinical trial with its peanut allergy therapeutic.Pharma-giantBayer was aleadinvestor in the round.

Cellino

Artificial intelligence is impacting the future of every industry, and the life sciences industry is no different. Using image-guided machine learning AI, Cambridge-based Cellinois guiding automated cell reprogramming, expansion and differentiation. Launchedin 2017, the company just completed a$16 million seed roundtoenable its induced pluripotent stem cell (iPSC) engineering platform, powered by artificial intelligence.Autologous iPSCs cells taken from a patient, engineered for therapeutic benefit and returned to the patient have been in clinical testing since 2014, but none have reached regulatory approval.Cellinos platform will allow it to precisely steer iPSCs to a target tissue state.

Endogena

Discovering and developing regenerative medicines from within,Endogenabrought in$8 millionin a Series A financing round last week.Focused on novel treatments for neurodegenerative diseases, the funds will help its lead program aimed at retinitis pigmentosa to establish clinical proof-of-concept.EndogenasAI-driven platform is a combination of stem cell research and small molecule drug discovery. The company also hopes to advance its age-related macular degeneration program to an IND.

AffyXell

Established last January to develop novel mesenchymal stem cell therapies,AffyXellclosed aSeries A for $7.3 millionto develop its pipeline of next-gen cell and gene therapies.The biotech combines Avacta TherapeuticssAffimerplatform withDaewoongPharmaceuticals MSC platform to genetically modify stem cells tosecreteAffimerproteins that enhance the therapeutic effectsof the MSC. Funds from the series will be used for further development oftherapies that will suppress immune response and restore balance for inflammatory and autoimmune diseases.

Most Read Today

See the rest here:
Money on the Move: January 27 February 2 - BioSpace